Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Fights For Viread Patent And Royalties In India

This article was originally published in PharmAsia News

Executive Summary

Gilead Sciences is challenging a decision in India refusing patent protection for its worldwide HIV blockbuster drug Viread (tenofovir)

You may also be interested in...



Relevant Pipeline Brings Gilead Closer to Direct Indian Presence

Long after it has established business links with Indian drug makers, Gilead Sciences is looking to set up its own India office. All these years, the US firm has stopped shy of a direct presence but the growing relevance of its drug pipeline to the local population now makes this a strategic imperative, say industry insiders.

A Closer Look: Gilead’s Viread Donation To China

Gilead’s decision to donate Viread to Chinese HIV patients came at a time when China was updating its compulsory license rules. The U.S. company may have also been thinking about the potential ramifications for hepatitis B, a much larger market in China.

China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs

Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.

Related Content

Latest News
UsernamePublicRestriction

Register

SC070671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel